if the efficacy is not in line with secondary outcomes for FGSG....what's the rationale behind phase 3? are they expecting sub analysis to potentially trim patient type narrow and expect it to work?
Ann: Quarterly Appendix 4C and Activities Report, page-205
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.045(10.2%) |
Mkt cap ! $266.8M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 49.0¢ | 44.0¢ | $2.019M | 4.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 15954 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |